Executive Interviews

51. Alnylam's Challenge: Scaling Up And Moving Beyond The Liver 8/1/2022

    Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient populations, and describes her own journey to the CEO role.  

52. KemPharm: Converting FDA Complete Response Letters Into New Opportunities 8/1/2022

    KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.

53. Venture Philanthropy Launches Biotech From Within 8/1/2022

    A summary of a discussion with Ben Yerxa, CEO of Opus Genetics, an early-stage gene therapy company launched in 2021 and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund.

54. A Network And Pivot Model For Success In Cancer Drug Development 7/1/2022

    When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.

55. Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper 7/1/2022

    Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days. 

56. Diversity & Inclusion Through The Eyes Of Two Female Pharma Executives 6/1/2022

    In the following, we present two first-hand accounts of what it has been like to be a female working in the pharma industry for many years, and what we can all do to overcome the industrywide challenge related to diversity and inclusion.

57. Leveling Up By Challenging Assumptions 6/1/2022

    An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.

58. 3 Approaches For Developing Better Drugs To Treat Brain Disorders 6/1/2022

    Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.

59. CoCrystal's Co-CEOs 6/1/2022

    Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

60. A New Model For A New Era Of Psychedelic Therapy 5/2/2022

    MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.